Sun, Sep 21, 2014, 6:48 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • mddroege mddroege Dec 19, 2011 3:05 PM Flag

    Superiority vs Non-inferiority trial

    Does anyone know why they did a non-inferiority trial instead of a superiority trial? Is a superiority trial the next step?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'm not an expert in this area but I think all novel antibiotic trials are non-inferiority. The idea is that we don't need antibiotics that are more effective, we just need new ones so that as bacteria develop resistance to existing drugs, we have something to fall back on.

      While the numbers are similar, remember that Trius' drug is a shorter course and only given 1/day. In my mind, if you can give less drug for a shorter period of time and get the same result, that is superior.

      • 1 Reply to markak1515
      • Exactly. If it is 'non-inferior'...then it is superior by default. That is the point everyone is missing. It targets bacteria that are resistant to existing treatments. Thus, if it can perform comparitively with existing treatments against non-resistant staph, it IS superior. Not to mention the shorter treatment regiment; smaller dosage; less side effects; etc. If we upped the dose and treatment length comparable to the Pfizer drug...and it proved tolerable, the numbers would be a blowout! It was comparable, even post-treatment, with 4 less treatment days!

 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.